Q-omics provides the consensus-scored MAIP1 profile across patient tissues and cancer cell-line models. MAIP1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MAIP1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MAIP1 protein abundance shows 24,136 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ESCA, KICH, and LSCC as cancer lineages where MAIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAIP1 survival associations across molecular data types. MAIP1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAIP1 RNA expression–survival associations across cancer types. High MAIP1 expression shows unfavorable associations in ESCA, ACC, UCEC, LUAD and CHOL, but favorable associations in KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for MAIP1 RNA expression.
This table summarizes MAIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAIP1 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in STAD, HNSC and LUAD. The KICH box plot shows higher MAIP1 RNA expression in normal versus tumor tissue (log2 FC = −1.381, t-test p < 0.001).
This table shows molecular features associated with MAIP1 in patient tissues and cancer cell lines. In patient samples, MAIP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
